ER 50891

• Description :

  ER 50891 is a RARα antagonist. ER 50891 can significantly antagonize the inhibitory effect of all-trans retinoic acid (ATRA) on the total cell metabolic activity and proliferation of MC3T3-E1 preosteoblasts. ER 50891 rescues ATRA-inhibited osteocalcin (OCN) expression and extracellular matrix mineralization, and suppresses alkaline phosphatase (ALP) activity synergistically. ER 50891 can be used for the study of osteoporosis related to ATRA-induced inhibition of osteoblastogenesis[1].

• UNSPSC :

  12352005

• Target :

  RAR/RXR

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/er-50891.html

• Purity :

  99.86

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(O)C1=CC=C(C2=CC=C(C3=NC4=C(C(C)C)C=CC=C4C(C5=CC=CC=C5)=C3)N2)C=C1

• Molecular Formula :

  C29H24N2O2

• Molecular Weight :

  432.51

• References & Citations :

  [1]Wang S, et al. The Antagonist of Retinoic Acid Receptor α, ER-50891 Antagonizes the Inhibitive Effect of All-Trans Retinoic Acid and Rescues Bone Morphogenetic Protein 2-Induced Osteoblastogenic Differentiation. Drug Des Devel Ther. 2020 Jan 22;14:297-308.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  RXRα

• CAS Number :

  [187400-85-7]